415 Capital

415 Capital invests in medical technologies at clinical through commercial stages, primarily in Europe, Israel, and North America. The firm targets sectors such as Structural Heart Disease, Heart Failure, Aortic & Peripheral Vascular Disease, Neurovascular Disease, Hypertension, Electrophysiology, Neuromodulation for Chronic Diseases, Medical Imaging, Medical Robotics, and Patient Monitoring. The firm does not invest in biotech/pharma, healthcare services, or wellness products.

Investment checks typically range from €5-15 million, allowing for significant contributions to promising startups. 415 Capital's investment thesis emphasizes improving patient outcomes in areas such as structural heart disease and neurovascular conditions, aligning with their goal of addressing significant unmet patient needs.

Notable active portfolio companies include:

• Endovascular Engineering: Developing a next-generation clot removal technology platform for venous thromboembolism (VTE).
• Laza Medical: Provides AI-powered cardiovascular robotics and imaging solutions to improve clinical workflows in structural heart and electrophysiology procedures.
• Supira Medical: Developing a low-profile, high continuous flow percutaneous ventricular assist device (pVAD) for high-risk PCI and cardiogenic shock patients.
• R3 Vascular: Focused on bioresorbable vascular scaffold technology for patients with peripheral vascular disease.
• CorFlow Therapeutics: Developing a system for accurate detection and targeted therapy of microvascular obstruction (MVO).
• Cardiac Success: Working on a minimally invasive transcatheter device to repair and reshape the left ventricle in heart failure patients.
• Hilo: Pioneering methods to track and optimize blood pressure control.
• Distalmotion: Innovating on-demand surgical robotics with its Dexter robotic platform.
• TRiCares: Developing a minimally invasive transcatheter technology for tricuspid valve replacement.

Notable exited investments include:

• Vesper Medical: Acquired by Royal Philips in 2021.
• CoRRect Medical: Acquired by Uniphar PLC in 2021.
• Intact Vascular: Acquired by Royal Philips in 2020.
• Mitralign: Acquired by Edwards Lifesciences in 2019.
• Claret Medical: Acquired by Boston Scientific in 2018.

Frederik Groenewegen - General Partner. He has extensive experience in venture capital and a strong background in medical technologies.

David Thompson - General Partner. He brings a wealth of knowledge in healthcare investments and has led numerous successful deals.

Azin Parhizgar - Managing Director, US. Azin has a deep understanding of the US healthcare market and has been instrumental in expanding 415 Capital's presence in North America.

Ruben Osnabrugge - Partner. He specializes in identifying and supporting innovative medical technology startups.

Linus Rieder - Principal. Linus focuses on deal sourcing and portfolio management, contributing to the firm's investment strategy.

Amra Hadziabdic - Executive Assistant. Amra supports the team with administrative tasks and project coordination.

Eduardo Palma - Senior Investment Analyst. Eduardo conducts due diligence and market analysis for potential investments.

Julia Hoffmeister - Investment Analyst. Julia assists in evaluating investment opportunities and supporting portfolio companies.

Matheus Abizaid - Visiting Investment Analyst. Matheus contributes to research and analysis efforts.

Yannik Wanner - Working Student. Yannik supports various projects within the firm.

Hershel Groenewegen - Chief Happiness Officer. Hershel focuses on team culture and employee well-being.

Senior Advisors include Frank Groenewegen - Chairman Emeritus, Michael Braun - Senior Venture Partner, and Steven Bolling - Senior Advisor.

To pitch to 415 Capital, founders should submit their business plans through the contact page on their website at 415capital.com/contact/. The pitch deck should include a clear overview of the technology, market opportunity, and team qualifications. Response times may vary, but founders are encouraged to seek warm introductions when possible to enhance their chances of engagement.

In 2021, 415 Capital realized notable exits with the acquisition of Vesper Medical by Royal Philips and CoRRect Medical by Uniphar PLC. Additionally, Intact Vascular was acquired by Royal Philips in 2020, and Mitralign was acquired by Edwards Lifesciences in 2019. These exits highlight the firm's successful track record in the medical technology sector.

415 Capital continues to actively engage in the venture capital space, focusing on investments in medical technologies that address significant unmet patient needs. Their portfolio includes innovative companies such as Endovascular Engineering and Laza Medical, reflecting their commitment to advancing healthcare solutions.